MenAfriVac is a vaccine developed to protect against meningococcal disease, specifically targeting serogroup A. This disease is caused by the bacterium Neisseria meningitidis and can lead to severe health complications such as meningitis and septicemia. The vaccine was specifically designed for use in the African meningitis belt, a region that has long been plagued by frequent and devastating epidemics.
